Zifrosilone (1-(3-trimethylsilylphenyl)-2,2,2-trifluoroethanone) (3) is a cholinesterase inhibitor that has been studied for the treatment of Alzheimer's disease. Process research has been carried out on a route to convert phenyltrimethylsilane to 3 by Friedel-Crafts acylation using trifluoroacetic anhydride. Kinetics and products analyses suggest that the optimal conditions for this reaction are noncatalytic amounts of aluminum chloride, dichloromethane solvent and as low a temperature as can be practically used in a scaled-up process. Significant separation challenges to isolate 3 from the isomer byproduct 1-(4-trimethylsilylphenyl)-2,2,2-trifluoroethanone) (4) remain. These challenges were investigated using vapor-liquid equilibrium studies.